Literature DB >> 1519522

Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study.

G Assmann1, H Schulte.   

Abstract

The incidence of atherosclerotic coronary artery disease (CAD) was assessed in 4,559 male participants (aged 40 to 64 years) from the Prospective Cardiovascular Münster study, over a 6-year follow-up period. During this time, 186 study participants developed atherosclerotic CAD (134 definite nonfatal myocardial infarctions and 52 definite atherosclerotic CAD deaths including 21 sudden cardiac deaths and 31 fatal myocardial infarctions). Univariate analysis revealed a significant association between the incidence of atherosclerotic CAD and high-density lipoprotein (HDL) cholesterol (p less than 0.001) and triglycerides (p less than 0.001). The relation to HDL cholesterol remained after adjustment for other risk factors. By contrast, the relation between the incidence of atherosclerotic CAD and triglycerides disappeared if, in a multivariate analysis by means of a multiple logistic function, cholesterol or HDL cholesterol were taken into account. However, the data suggested that hypertriglyceridemia is a powerful additional coronary risk factor, when excessive triglycerides coincide with a high ratio of plasma low-density lipoprotein cholesterol to HDL cholesterol (greater than 5.0). Even though the prevalence of this subgroup was only 4.3%, it included a quarter of all atherosclerotic CAD events observed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1519522     DOI: 10.1016/0002-9149(92)90550-i

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  109 in total

Review 1.  Impact of dyslipidaemia. Lessons from clinical trials.

Authors:  W V Brown
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

Review 2.  Resource utilisation in the management of dyslipidaemia.

Authors:  T D Szucs
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

3.  Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias.

Authors:  J G Fodor; J J Frohlich; J J Genest; P R McPherson
Journal:  CMAJ       Date:  2000-05-16       Impact factor: 8.262

Review 4.  Abdominal adipose tissue distribution and metabolic risk.

Authors:  Suzy Wong; Ian Janssen; Robert Ross
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

5.  Hypoalphalipoproteinemia.

Authors:  J J Frohlich
Journal:  CMAJ       Date:  1992-12-15       Impact factor: 8.262

Review 6.  Are lower levels of low-density lipoprotein cholesterol beneficial? a review of recent data.

Authors:  Anders G Olsson
Journal:  Curr Atheroscler Rep       Date:  2006-09       Impact factor: 5.113

Review 7.  Management of lipid disorders in the elderly.

Authors:  D A Playford; G F Watts
Journal:  Drugs Aging       Date:  1997-06       Impact factor: 3.923

8.  Effects of Cacao By-Products and a Modest Weight Loss Intervention on the Concentration of Serum Triglycerides in Overweight Subjects: Proof of Concept.

Authors:  Perla León-Flores; Nayelli Nájera; Elizabeth Pérez; Blanca Pardo; Fiacro Jimenez; Dylan Diaz-Chiguer; Francisco Villarreal; Isabel Hidalgo; Guillermo Ceballos; Eduardo Meaney
Journal:  J Med Food       Date:  2020-04-15       Impact factor: 2.786

Review 9.  Statin therapy in the elderly: does it make good clinical and economic sense?

Authors:  Moira M B Mungall; Allan Gaw; James Shepherd
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

10.  Linkage and association between distinct variants of the APOA1/C3/A4/A5 gene cluster and familial combined hyperlipidemia.

Authors:  Sophie Eichenbaum-Voline; Michael Olivier; Emma L Jones; Rossitza P Naoumova; Bethan Jones; Brian Gau; Hetal N Patel; Mary Seed; D John Betteridge; David J Galton; Edward M Rubin; James Scott; Carol C Shoulders; Len A Pennacchio
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-10-09       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.